{{medical}}

{{Infobox drug
| Verifiedfields = correct
| Watchedfields = correct
| verifiedrevid = 456481815
| IUPAC_name = (±)-N-methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine
| image             = Fluoxetine2DACS.svg
| image2            = Fluoxetine3Dan.gif
| caption           = 
| drug_name         = 氟西汀<br />Fluoxetine
| tradename         = 百憂解（Prozac）、Animex-On、Sarafem、Adofen、Deprex
| Drugs.com         = {{drugs.com|monograph|fluoxetine-hydrochloride}}
| MedlinePlus       = a689006
| licence_US        = Fluoxetine
| pregnancy_AU      = C
| pregnancy_US      = C
| legal_AU          = S4
| legal_CA          = Rx-only
| legal_UK          = POM
| legal_US          = Rx-only

| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number        = 54910-89-3
| ATC_prefix        = N06
| ATC_suffix        = AB03
| PubChem           = 3386
| IUPHAR_ligand     = 203
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00472
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID      = 3269
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 01K63SUP8D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG              = D00326
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI             = 5118
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL            = 41
| molecular_weight  = 309.33 g·mol<sup>−1</sup>
| smiles            = CNCCC(c1ccccc1)Oc2ccc(cc2)C(F)(F)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI          = 1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey       = RTHCYVBBDHJXIQ-UHFFFAOYSA-N
| C = 17 | H = 18 | F = 3 | N = 1 | O = 1

| addiction_liability = 无
| dependency_liability = 生理：低<br />心理：低
| onset             = ~2–4周
| routes_of_administration = 口服
| bioavailability = 72%<ref name ="PK">{{cite journal |title=Clinical Pharmacokinetics of Fluoxetine |journal=Clinical Pharmacokinetics |date=March 1994 |volume=26 |issue=3 |pages=201–214 |doi = 10.2165/00003088-199426030-00004 |pmid=8194283 |authors=Altamura, AC; Moro, AR; Percudani, M |url = http://link.springer.com/content/pdf/10.2165/00003088-199426030-00004.pdf |format = PDF }}</ref>
| protein_bound = 94-95%<ref name="PK" /><ref name ="DM">{{cite web|title=FLUOXETINE HYDROCHLORIDE capsule [Sandoz Inc]|work=DailyMed|publisher=Sandoz Inc|date=January 2013|accessdate=23 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db1c840d-ab22-4a4c-9ced-ae82c869dd9b|archive-date=2013-12-03|archive-url=https://web.archive.org/web/20131203011159/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db1c840d-ab22-4a4c-9ced-ae82c869dd9b|dead-url=no}}</ref><ref name="MSR">{{cite web |title = Prozac, Sarafem (fluoxetine) dosing, indications, interactions, adverse effects, and more |work = Medscape Reference |publisher = WebMD |accessdate = 23 November 2013 |url = http://reference.medscape.com/drug/prozac-sarafem-fluoxetine-342955 |archive-date = 2015-09-06 |archive-url = https://web.archive.org/web/20150906094023/http://reference.medscape.com/drug/prozac-sarafem-fluoxetine-342955 |dead-url = no }}</ref>
| metabolism = [[肝脏|肝脏]] (大部分是[[CYP2D6|CYP2D6]]-介导的)<ref name="PK" /><ref name = TGA/>
| elimination_half-life = 1–3天（急性高剂量）<br />4–6天（维持剂量）<ref name="PK" /><ref name = TGA/>
| excretion = 尿液（80%）、粪便（15%）<ref name ="PK" /><ref name= "TGA">{{cite web |title=PROZAC® Fluoxetine Hydrochloride |work=TGA eBusiness Services |publisher=Eli Lilly Australia Pty. Limited |date=9 October 2013 |accessdate=23 November 2013 |url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04098-3 |format=PDF |archive-date=2017-04-25 |archive-url=https://web.archive.org/web/20170425231029/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04098-3 |dead-url=no }}</ref>
| melting_point     = 179
| melting_notes     = 
| melting_high      = 182
| boiling_point     = 395
| boiling_notes     = 
| solubility        = 14
}}

<!-- 定义及用途 -->
'''氟西汀'''（{{lang-en|'''Fluoxetine'''}}），商品名为'''百憂解'''（'''Prozac'''）是一种[[选择性5-羟色胺再摄取抑制剂|选择性5-羟色胺再摄取抑制剂]]（SSRI）类[[抗抑郁药|抗抑郁药]]<ref name="AHFS2015">{{cite web |title = Fluoxetine Hydrochloride |url = http://www.drugs.com/monograph/fluoxetine-hydrochloride.html |publisher = The American Society of Health-System Pharmacists |accessdate = 2015-10-02 |archive-date = 2015-12-08 |archive-url = https://web.archive.org/web/20151208193110/http://www.drugs.com/monograph/fluoxetine-hydrochloride.html |dead-url = no }}</ref>。在臨床上用於治療成人[[重性抑郁障碍|重性抑郁障碍]]、[[强迫症|强迫症]]、[[神經性暴食症|神經性暴食症]]、[[社交恐懼症|社交恐懼症]]<ref name="百優解說明書">{{cite book|title = 鹽酸氟西汀分散片說明書 |author = 禮來公司 |publisher = 禮來公司 |year = 2007年}}</ref><ref name="百優解產品介紹">{{cite web |url = http://www.lillychina.com/products/byj.html |title = 產品介紹——百優解 |author = [[禮來公司|禮來公司]] |accessdate = 2008-07-11 |archive-url = https://web.archive.org/web/20080705115405/http://www.lillychina.com/products/byj.html |archive-date = 2008-07-05 |dead-url = yes }}</ref>，還用於治療具有或不具有[[廣場恐懼症|廣場恐懼症]]的[[驚恐症|驚恐症]]<ref>{{cite web |url = |title = Prozac Label |author = FDA/Center for Drug Evaluation and Research}}</ref>

此药或可降低超过65岁人群的自杀风险。此药经口服用<ref name="AHFS2015" />。

<!-- 副作用 -->
氟西汀的常见副作用有睡眠不安、食欲减退、口干、皮疹、怪梦<!-- <ref name="AHFS2015" /> -->。较为严重的副作用有[[血清素综合症|血清素综合症]]、{{tsl|en|mania|躁狂|}}、[[癫痫|癫痫]]、出血风险增加，以及少于25岁者[[自殺|自殺]]风险增加<!-- <ref name="AHFS2015" /> -->。突然停药可能会引发{{tsl|en|SSRI discontinuation syndrome|SSRI戒断综合症|戒断综合症}}，导致焦虑、[[头晕|头晕]]，感官变化<ref name="AHFS2015" />。此药不安全用于[[妊娠|孕期]]會影響寶寶發展<!-- <ref name="PB2015" /> -->。如果之前已在使用此药，在[[母乳餵養|母乳餵養]]期间應停止使用<ref name="PB2015">{{cite web |title = Fluoxetine Pregnancy and Breastfeeding Warnings |url = http://www.drugs.com/pregnancy/fluoxetine.html |accessdate = 2 December 2015 |archive-date = 2017-07-03 |archive-url = https://web.archive.org/web/20170703134228/https://www.drugs.com/pregnancy/fluoxetine.html |dead-url = no }}</ref>。此药作用机理尚未完全阐明，一般认为可能和脑中[[血清素|血清素]]活动增加有关<ref name="AHFS2015" />。

<!-- 历史、社会、文化 -->
氟西汀由[[礼来公司|礼来公司]]于1972年发现，1986年投入医疗用途<ref>{{cite book |last1=Myers |first1=Richard L. |title=The 100 most important chemical compounds : a reference guide |year=2007 |publisher=Greenwood Press |location=Westport, Conn. |ISBN=9780313337581 |page=128 |edition=1. publ. |url=https://books.google.ca/books?id=MwpQWcIKMzAC&pg=PA128 |access-date=2017-01-27 |archive-date=2017-08-31 |archive-url=https://web.archive.org/web/20170831175706/https://books.google.ca/books?id=MwpQWcIKMzAC&pg=PA128 |dead-url=no }}</ref>。此药属[[世界卫生组织基本药物标准清单|世界卫生组织基本药物]]，为基本[[卫生系统|卫生系统]]所需的最重要药品之一<ref>{{cite web |title = WHO Model List of Essential Medicines |format = PDF |url = http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1 |work = World Health Organization |accessdate = 22 April 2014 |date = October 2013 |archive-date = 2014-04-23 |archive-url = https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1 |dead-url = no }}</ref>。此药现为一种[[通用名药物|通用名药物]]<ref name="AHFS2015" />。{{as of|2014}}，批发价格约为每日剂量0.01到0.04美元<ref>{{cite web |title = Fluoxetine |url = http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=FLU20T&s_year=2014&year=2014&str=20%20mg&desc=Fluoxetine&pack=new&frm=TAB-CAP&rte=PO&class_code2=24%2E2%2E1%2E&supplement=&class_name=%2802%2E3%2E%29Medicines%20for%20other%20common%20symptoms%20in%20palliative%20care%3Cbr%3E%2824%2E2%2E1%2E%29Medicines%20used%20in%20depressive%20disorders%3Cbr%3E |website = International Drug Price Indicator Guide |accessdate = 2015-12-02 }}{{Dead link|date=2018年6月 |bot=InternetArchiveBot |fix-attempted=no }}</ref>。而在美国每日花费约为0.85美元<ref name="AHFS2015" />。

儘管現在已有不少較新的藥物，氟西汀在臨床應用中依然十分常用。在2010年，美國醫療機構總共開出超過2440萬次氟西汀的處方，此时氟西汀已是美國市場上第三常用抗憂鬱藥物（位於[[舍曲林|舍曲林]]和[[西酞普兰|西酞普兰]]之後）<ref name="generic drugs 2010">{{cite web |url = http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf |title=Top 200 Generic Drugs by Units in 2010 |author=Verispan |format=PDF |publisher=Drug Topics |deadurl=yes |archiveurl = https://web.archive.org/web/20121215070930/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf |archivedate=2012-12-15 }}</ref>。

== 歷史 ==

根據百優解的主要發明者 David Wong 所述<ref name=Wong>{{cite journal en |author=  Wong, DT, Bymaster FP, Engleman EA |title=Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication |journal=Life Sci |volume=57 |issue=5 |pages=411–41 |year=1995 |pmid=7623609 |doi=10.1016/0024-3205(95)00209-O}}</ref>，和發現氟西汀有關的工作最早開始於 Bryan Molloy 和 Robert Rathburn 1970年在[[禮來公司|禮來公司]]的合作研究。當時醫學界已知[[抗組胺劑|抗組胺劑]][[苯海拉明|苯海拉明]]有一定的抗憂鬱效果，因此他們從與其分子結構類似的 3-Phenoxy-3-phenylpropylamine 開始，合成了其數十種衍生變體並在小鼠上測試其生理作用，最後得到一種後來被廣泛使用在生化實驗中的[[選擇性去甲腎上腺素再吸收抑制劑|選擇性去甲腎上腺素再吸收抑制劑]]——[[尼索西汀|尼索西汀]]（Nisoxetine）。

後來 Wong 提議對[[血清素|血清素]]、[[去甲腎上腺素|去甲腎上腺素]]和[[多巴胺|多巴胺]]的體外再吸收做重新測試，以期能得到一種僅抑制血清素再吸收的衍生變體。1972年5月，Jong-Sir Horng 根據這一提議得到了氟西汀<ref>{{cite journal |author=Wong D, Horng J, Bymaster F, Hauser K, Molloy B |title=A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine |journal=Life Sci |volume=15 |issue=3 |pages=471–9 |year=1974 |pmid=4549929 |doi=10.1016/0024-3205(74)90345-2}}</ref> 。禮來公司據此生產的抗憂鬱藥百優解1986年在[[比利時|比利時]]首先獲准上市用於憂鬱症的治療<ref>{{Citation |last = Swiatek |first = Jeff |title = Prozac's profitable run coming to an end for Lilly |newspaper = The Indianapolis Star |date = August 2, 2001 |url = http://www2.indystar.com/library/factfiles/business/companies/lilly/stories/2001_0802.html |deadurl = yes |archiveurl = https://web.archive.org/web/20070818163109/http://www2.indystar.com/library/factfiles/business/companies/lilly/stories/2001_0802.html |archivedate = 2007年8月18日 }}</ref>，1987年底獲得美國食品與藥品管理局（FDA）批准進入美國市場<ref>{{cite web| title =Electronic Orange Book| publisher =Food and Drug Administration| date =April 2007| url =http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=018936&TABLE1=OB_Rx| accessdate =May 24, 2007| archive-date =2007-08-20| archive-url =https://web.archive.org/web/20070820013552/http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=018936&TABLE1=OB_Rx| dead-url =no}}</ref>。

禮來公司對百憂解的專利於2001年8月過期<ref>{{cite web
|title=Patent Expiration Dates for Common Brand-Name Drugs
|url=http://www.express-scripts.com/pharmacist/notifications/docs/genericdrugs.htm
|accessdate=2007-07-20
|archive-date=2007-09-28
|archive-url=https://web.archive.org/web/20070928201304/http://www.express-scripts.com/pharmacist/notifications/docs/genericdrugs.htm
|dead-url=no
}}</ref>，此後市場上出現了一大批氟西汀藥物。

== 藥理及藥代 ==

[[File:Prozac_pills.jpg|thumb]]

氟西汀是一種選擇性血清素（5-羥色胺，5-HT）再吸收抑制劑，通過抑制神經突觸細胞對神經遞質血清素的再吸收以增加細胞外可以和突觸後受體結合的血清素水平。而對其它受體，如α-腎上腺素能、β-腎上腺素能、5-羥色胺能、多巴胺能等，氟西汀則幾乎沒有結合力。<ref name="百優解說明書" />

氟西汀口服後從胃腸道吸收良好，進食不影響其[[生物利用度|生物利用度]]。吸收後與[[血漿蛋白|血漿蛋白]]大量結合，分佈廣泛。服藥數周後達到穩態血漿濃度。<ref name="百優解說明書" />

氟西汀基本由肝臟代謝，通過[[去甲基化作用|去甲基化作用]]生成[[活性代謝產物|活性代謝產物]][[去甲氟西汀|去甲氟西汀]]（demethylfluoxetine）。氟西汀的消除半衰期為4-6天，去甲氟西汀則為4-16天。主要經腎臟排泄。由於可分泌至母乳，<ref name="百優解說明書" /> 所以建議向孕婦及哺乳期婦女處方要謹慎。

在多項針對憂鬱症患者進行的安慰劑和活性藥物對照臨床試驗中，以[[漢密頓憂鬱量表|漢密頓憂鬱量表]]（HAM-D）作為評估工具，已經證實氟西汀對憂鬱症的療效明顯優於安慰劑。針對強迫症和神經性厭食症患者的試驗也有類似的結論。<ref name="百優解說明書" />

==已知可能後遺症==
[[:SSRI后的性功能障碍|PSSD(Post-SSRIs sexual dysfunction)]]：SSRI後的性功能障礙

== 不良反應及副作用 ==

根據禮來公司百優解的使用說明書<ref name="百優解說明書" /><ref name="百優解產品介紹"/>，服用氟西汀的常見不良反應有：全身或局部過敏，胃腸道功能紊亂（如噁心、嘔吐、消化不良、腹瀉、吞嚥困難等），心跳加速，厭食，頭暈、頭痛，睡眠異常，疲乏，精神狀態異常，性功能障礙，視覺異常，呼吸困難等等。 對於正在使用[[單胺氧化酶抑制劑|單胺氧化酶抑制劑]]（MAOI）等藥物者，應禁用氟西汀。對於肝功能不全者，氟西汀和去甲氟西汀的半衰期分別增至7天和14天，因此應考慮減少用藥劑量或降低用藥頻率。

美國食品藥物管理局公佈指出所有抗憂鬱藥都有增加年輕人自殺可能性的風險<ref name=FDA>{{cite web| author = Levenson M, Holland C| title = Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)| accessdate = 2007-05-13| url = http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt| archive-date = 2017-05-17| archive-url = https://web.archive.org/web/20170517031649/https://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt| dead-url = no}}</ref><ref name =FDA2>{{cite web | url = http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf | title = Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults | accessdate = 2007-09-22 | author = Stone MB, Jones ML | authorlink =  | coauthors =  | date = 2006-11-17 | format = PDF | work = Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC) | publisher = FDA | pages = 11-74 | language =  | archiveurl = https://web.archive.org/web/20070316092329/http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf | archivedate = 2007-03-16 | quote =  | dead-url = no }}</ref><ref name =FDA3>{{cite web | url = http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf | title = Statistical Evaluation of Suicidality in Adults Treated with Antidepressants | accessdate = 2007-09-22 | author = Levenson M, Holland C | authorlink =  | coauthors =  | date = 2006-11-17 | format = PDF | work = Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC) | publisher = FDA | pages = 75-140 | language =  | archiveurl = https://web.archive.org/web/20070316092329/http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf | archivedate = 2007-03-16 | quote =  | dead-url = no }}</ref><ref name="pmid16395296">{{cite journal |author=Klein DF |title=The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children |journal=Neuropsychopharmacology |volume=31 |issue=4 |pages=689–99 |year=2006 |pmid=16395296 |doi=10.1038/sj.npp.1300996}}</ref><ref name="pmid18190232">{{cite journal |author=Mann JJ, Ellis SP, Waternaux CM, Liu X, Oquendo MA, Malone KM, Brodsky BS, Haas GL, Currier D |title=Classification Trees Distinguish Suicide Attempters in Major Psychiatric Disorders: A Model of Clinical Decision Making |journal=J Clin Psychiatry |volume= |issue= |pages=e1–e9 |year=2008 |pmid=18190232 |doi=}}</ref>。也有實驗指出服用氟西汀後，對於小孩可能增加了自殺可能性，而對於成人則可能減小了自殺可能性<ref name =FDA2/><ref name =FDA3/><ref name =FDA4>{{cite web | url = http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1_08_FDA-Hammad.ppt | title = Results of the Analysis of Suicidality in Pediatric Trials of Newer Antidepressants | accessdate = 2008-01-06 | author = Tarek A. Hammad | authorlink =  | coauthors =  | date = 2004-09-13 | format = PDF | work = Presentation at the Meeting of Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee on September 13, 2004 | publisher = FDA | pages = 25, 28 | language =  | archiveurl = https://web.archive.org/web/20080228024710/http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1_08_FDA-Hammad.ppt | archivedate = 2008-02-28 | quote =  | dead-url = no }}</ref><ref>{{cite web |author=[[Committee_on_Safety_of_Medicines|Committee on Safety of Medicines]] Expert Working Group |title=Report on The Safety of Selective Serotonin Reuptake Inhibitor Antidepressants |url=http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf |accessdate=2007-09-25 |date=December 2004 |format=PDF |publisher=[[Medicines_and_Healthcare_products_Regulatory_Agency|MHRA]] |archive-date=2014-08-21 |archive-url=https://web.archive.org/web/20140821100902/http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf |dead-url=yes }}</ref><ref name="pmid15718537">{{cite journal |author=Gunnell D, Saperia J, Ashby D |title=Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review |journal=BMJ |volume=330 |issue=7488 |pages=385 |year=2005 |pmid=15718537 |doi=10.1136/bmj.330.7488.385|accessdate=2007-09-25}}</ref>。

此外，亦有報導稱服用氟西汀可能引起暴力傾向增強<ref>{{cite web|url=http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030372&ct=1|title=Antidepressants and Violence: Problems at the Interface of Medicine and Law|author=David Healy, Andrew Herxheimer, and David B. Menkes|journal=PLoS Med|issue=3(9): e372|doi=10.1371/journal.pmed.0030372|year=2006|accessdate=2020-09-12|archive-date=2009-03-20|archive-url=https://web.archive.org/web/20090320231102/http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371%2Fjournal.pmed.0030372&ct=1|dead-url=no}}</ref>。

臨床發現大劑量的服用氟西汀可能導致一些患者出現[[藥物性孤獨症|藥物性孤獨症]]。但是停用後症狀會消失。

=== 濫用可能性 ===

根據醫學上對濫用藥物的定義，由於氟西汀不會干擾多巴胺的分泌水平，因此[[FDA|FDA]]不認為氟西汀可被濫用<ref name=answersdotcom>{{cite web |url=http://wiki.answers.com/Q/Can_you_get_high_on_fluoxetine |title=Can you get high on fluoxetine? |accessdate=2011-08-29 |language=en |archive-date=2011-11-23 |archive-url=https://web.archive.org/web/20111123042645/http://wiki.answers.com/Q/Can_you_get_high_on_fluoxetine |dead-url=no }}</ref>。不過，亦有報告指「不影響多巴胺水平」只表示有關藥物不容易成癮，但不表示不會令人興奮<ref name=answersdotcom />。現時氟西汀的安全份量訂為約每周300-600毫克。

=== 安全用量 ===
根據[[禮來公司|禮來公司]]對其產品Prozac的詳細說明，藥廠根據在狗隻上的實驗結果，建議每日攝取份量不可超過80毫克，否則會引起肝代謝不良<ref name=lilly>{{Cite web |url=http://pi.lilly.com/us/prozac.pdf |title=存档副本 |accessdate=2012-02-13 |archive-date=2016-03-03 |archive-url=https://web.archive.org/web/20160303230434/http://pi.lilly.com/us/prozac.pdf |dead-url=no }}</ref>。現時在已知的接近200宗服用氟西汀致死的病例，死者均服用了數百毫克（超過20粒）份量的氟西汀<ref name=lilly />。

== 参考文献 ==
{{Reflist|30em}}

== 外部連結 ==

* {{Commons category-inline|Fluoxetine}}
{{-}}
{{抗抑郁药}}
{{OCD pharmacotherapies}}
{{Sigmaergics}}

[[Category:选择性血清素重摄取抑制剂|Category:选择性血清素重摄取抑制剂]]
[[Category:礼来公司|Category:礼来公司]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:苯醚|Category:苯醚]]
[[Category:三氟甲苯|Category:三氟甲苯]]